Gadoversetamide is a gadolinium-based MRI contrast agent, particularly for imaging of the brain, spine and liver.[1][2] It is marketed under the trade name OptiMARK.
Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
License data | |
Routes of administration | Intravenous |
ATC code | |
Pharmacokinetic data | |
Protein binding | Nil |
Metabolism | Nil |
Elimination half-life | 80 to 120 minutes |
Excretion | Renal |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H34GdN5O10 |
Molar mass | 661.77 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Notes
edit- ^ "Gadoversetamide Drug Information". Drugs.com. 2000-03-20. Archived from the original on 2007-10-10. Retrieved 2007-03-23.
- ^ Cheng KT (10 December 2007). "Gadoversetamide: Gd-DTPA-BMEA". Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US). PMID 20641436.